“There will be significant costs involved with getting approval for an OTC S3 product with the biggest hurdle identifying and proving the product is medically beneficial in some way”
they already have these costs covered in the most recent cap raise.
”Happy to hear the thoughts of others as always, I for one continue to be glad they are minimising debt and continue to raise money in other ways”.
I disagree. I would rather they avoid further dilution with any more cap raise and extend the debt facility. My bet/hope is they will get a variation from nab for the debt facility to include working capital and extend it ‘x’ million to address previous post around being able to increase revenue 70% year over year, I say why not? Cann currently cultivate 1.5 tonne, next CY they will be cultivating 14tonne. That’s a lot more than 70% increase in product... like I have said previously, it all comes down to how much product they can move.
CAN Price at posting:
29.0¢ Sentiment: Buy Disclosure: Held
(20min delay)